Blogs | MedChemExpress

Etrolizumab (rhuMAb Beta7) is a Gut-selective, Anti-β7 Integrin McAb for Inflammatory Bowel Disease (IBD) Research

2022-11-05

Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab decreases β7 integrins of T lymphocytes. Etrolizumab can be used for the research of inflammatory bowel disease.
Pelecopan (BCX9930) is a Selective, Orally Active Complement Factor D Inhibitor

2022-08-20

Pelecopan is a potent, selective, and orally active complement factor D inhibitor, possessing the potential to study paroxysmal nocturnal hemoglobinuria (PNH).
BM213 is a Potent and Selective Agonist of Complement C5a Receptor 1

2022-03-28

BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
CL097 is a TLR7/8 Agonist, Induces Pro-Inflammatory Cytokines

2022-01-28

CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
EMD527040 is a Highly Selective αvβ6 Antagonist with Antifibrotic Activities

2021-07-14

EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
Butaprost is a Selective Prostaglandin E Receptor (EP2) Agonist

2021-05-27

Butaprost is a selective prostaglandin E receptor (EP2) agonist. Butaprost can effectively mitigate kidney fibrogenesis in various fibrosis models.
CC-90001 is a Selective and Orally Active Inhibitor of JNK

2021-03-10

CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
Giredestrant (GDC-9545) is an Orally Active and Selective ER Antagonist

2020-10-14

Giredestrant (GDC-9545) is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant has highly potent in vivo efficacy with anti-tumor activity.
Molnupiravir (EIDD-2801) is an Orally Active Antiviral Compound Against COVID-19 and Influenza Virus

2020-04-18

Molnupiravir is a potent broad-spectrum antiviral agent. Molnupiravir shows antiviral effects against SARS-CoV in vivo by oral administration. Molnupiravir has the potential for COVID-19, and seasonal and pandemic influenza treatment.
Adagrasib (MRTX849) is an Orally Active and Covalent Inhibitor of KRAS^G12C

2019-11-17

Adagrasib (MRTX849) is an orally active and covalent inhibitor of KRAS^G12C. Adagrasib effects KRAS^G12C modification, inhibits KRAS inhibition and shows anti-tumor efficacy.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (17)